48 results
The objective of this study is the visualisation of diffuse and focal lesion in the brain in Multiple Sclerosis on higher main magnetic fields. Images from 1.5 Tesla MR scanners will be compared with images acquired at 3 Tesla and images made on 3…
In this study we would like to investigate whether cerebral perfusie and cerebral metabolism can be influenced with pharmacological agents in patients with MS and in healthy control persons. Cerebral perfusion and cerebral metabolism wil be measured…
In our longitudinal study we would like to investigate whether measures of neuronal damage, glial damage and oxidative stress are correlated with the speed of progression of disability. We would also like to investigate whether these variables…
How important is fatigue in patients with MTBI? What are the mechanisms underlying the decline in force during a fatiguing task? Which changes in brain activation take place during the fatiguing task?
We aim to determine the difference in uni- and bimanual coordination between young adults, older adults and MS patients. Additionally we want to determine the relation between the different measures of cortical inhibition and task performance.
Primary objectiveTo assess the safety and tolerability after single and multiple intravenous administrations of PPSGG in patients suffering from anti-MAG neuropathy.Secondary objectives- To evaluate the PK of PPSGG after single and multiple…
This pilot study aims to explore whether and why the cardiorespiratory fitness is compromised in newly diagnosed patients with early Relapsing Remitting Multiple Sclerosis (RRMS) with no or minimal clinical symptoms (i.e. Expanded Disability Status…
The main objective of this project is to identify the early brain changes in MS (i.e. patients that are recently diagnosed with MS) that can be measured by advanced structural and functional (network) imaging measures. Additionally, we will…
The purpose of this study is to assess the feasibility of decoding multiple movements from sensorimotor cortex of people with late-stage ALS and healthy controls.
This study has been transitioned to CTIS with ID 2024-510630-40-00 check the CTIS register for the current data. The objective of this prospective, randomized study is to investigate the efficacy and safety of HSCT compared to the comparator group (…
The primary objective of the study is to investigate changes in white matter structural integrity in patients with relapsing remitting multiple sclerosis (MS) after treatment with dimethyl fumarate and its relation to physical and cognitive…
1. To investigate the non-inferiority of blended CBT compared to proven effective face-to-face CBT according to the TREFAMS-CBT treatment protocol in severely fatigued patients with MS, using a non-inferiority margin of 5.3 points on the Checklist…
To identify prognostic factors for disease course and severity, as soluble and cellular biomarkers, immunological, genetic, radiological and demographics factors.
With this study we aim to prove that personalized B cell tailored ocrelizumab treatment is non-inferior in the suppression of MS disease activity (clinically and radiologically) compared to the standard (fixed 24 week interval) treatment.
(1) To compare the efficacy of two innovative preventative interventions with a control intervention in improving quality of life, cognition, work participation and productivity, brain plasticity and resilience, (2) to gain insight into the…
The goal of the fenebrutinib development program in MS is to evaluate the benefits and risks of fenebrutinib treatment across the spectrum of patients with MS. Based on the existing toxicology, pharmacology, and clinical experience with fenebrutinib…
The main objective of this project is to build a comprehensive model for a better predictio n of progression in MS, as a first step to move towards personalized prediction. Secondary objectives aim to study specific aspects of underlying mechanisms…
To describe the efficacy and safety of a maintenance versus induction anti-CD20 treatment strategy in pwMS.
To assess the efficacy of add-on high-dose simvastatin on markers for disease progression in MS patients treated with natalizumab or ocrelizumab for at least six months.
In the current *proof of principle* study, it is hypothesized that ex vivo expansion of Tregs originating from patients with the prototypic examples from the spectrum of autoimmune or inflammatory diseases (SLE, AAV, MS or CD) can be accomplished by…